FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
This article was originally published in The Pink Sheet Daily
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
You may also be interested in...
Both tablets and huge TVs have proliferated since the last research of the impact of superimposed text.
First Amendment litigation and guidance document work may be factors behind decline.
Booth promotion for Nembutal fails to disclose any risk information, Office of Prescription Drug Promotion says in the fifth letter issued this year.